Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France, that develops, manufactures, and commercializes prophylactic vaccines targeting infectious diseases with significant ... Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France, that develops, manufactures, and commercializes prophylactic vaccines targeting infectious diseases with significant unmet medical needs. Its commercial portfolio features three key vaccines: IXIARO®, for Japanese encephalitis; DUKORAL®, against cholera and traveler's diarrhea; and IXCHIQ®, a single-dose live-attenuated vaccine for chikungunya virus, serving travelers, military personnel, and outbreak preparedness in high-risk regions. Valneva SE maintains manufacturing sites in Livingston, Scotland; Solna, Sweden; and Vienna, Austria, supporting an integrated biotech model with over 700 employees across six countries. The company's innovative R&D pipeline includes VLA15, the world's most advanced Lyme disease vaccine candidate partnered with Pfizer, advancing to Phase 3 data readout in H1 2026; S4V2, a tetravalent Shigella bioconjugate vaccine; and preclinical assets like VLA2112 for EBV. With 2024 revenues around €169.6 million from its cash-generating commercial business, Valneva SE focuses on driving growth, strategic partnerships, and advancing first-in-class vaccines to achieve sustained profitability and global impact in preventing vaccine-preventable diseases.
Energy Management data not yet covered for Valneva
We have not yet reviewed Valneva's disclosures for Energy Management data.
If this data is relevant to your work, you can submit a data coverage request and our team
will investigate the company's disclosures and capture the data if available.
Account Restricted
Your account has been restricted and you no longer have access to paid features.
Contact our support team
or
upgrade your plan
to unblock your account.